lt

Visi / NYSE / NUVB.US

Nuvation Bio

Nuvation Bio

Investuok be komisinių

Pirk ir parduok dalines akcijas vos už 1 €

1 D.
1 SAV.
1 MĖN.
3 MĖN.
1 M.
MAKS.

Informacija ir statistika

Dienos intervalas
1 D.−100,00 %
3 MĖN.−100,00 %
1 SAV.−100,00 %
6 MĖN.−100,00 %
1 MĖN.−100,00 %
1 M.−100,00 %
SIMBOLIS
NUVB
RINKA
NYSE
ISIN
US67080N1019

Data

Uždara

Pokytis

Pokytis (%)

Atvira

Didelė

Maža

5,980,284,68 %5,706,045,65
5,760,162,78 %5,605,905,58
5,560,081,44 %5,485,605,30
5,330,193,56 %5,145,375,08
5,12−0,02−0,39 %5,145,285,02
5,140,101,95 %5,045,194,85
4,920,061,22 %4,865,224,85
4,760,224,62 %4,544,834,44
4,58−0,34−7,42 %4,924,984,49
4,93−0,18−3,65 %5,115,674,54
4,80−0,09−1,87 %4,894,984,74
4,82−0,28−5,81 %5,105,174,69
5,170,468,9 %4,715,434,71
4,72−0,12−2,54 %4,844,884,57
4,90−0,08−1,63 %4,985,004,66
4,960,234,64 %4,735,034,70
4,780,071,46 %4,714,814,59
4,75−0,02−0,42 %4,774,824,61
4,740,030,63 %4,715,054,65
4,69−0,10−2,13 %4,794,814,60
4,72−0,12−2,54 %4,844,924,61
4,790,438,98 %4,364,864,34
4,510,255,54 %4,264,604,21
4,240,081,89 %4,164,304,05
4,21−0,14−3,33 %4,354,424,16
4,32−0,34−7,87 %4,664,694,23
4,72−0,20−4,24 %4,924,924,64
4,780,000 %4,784,894,67
4,840,081,65 %4,764,904,63
4,760,030,63 %4,734,894,71
4,79−0,06−1,25 %4,854,924,67
4,81−0,21−4,37 %5,025,134,69
5,040,071,39 %4,975,184,78
4,830,5110,56 %4,324,874,10
4,41−0,10−2,27 %4,514,864,37
4,490,081,78 %4,414,564,35
4,45−0,01−0,22 %4,464,514,30
4,34−0,15−3,46 %4,494,514,19
4,56−0,04−0,88 %4,604,644,44
4,56−0,28−6,14 %4,845,174,51
4,89−0,13−2,66 %5,025,154,74
5,04−0,07−1,39 %5,115,254,96
5,12−0,14−2,73 %5,265,305,05
5,11−0,03−0,59 %5,145,275,00
5,120,081,56 %5,045,204,86
5,080,203,94 %4,885,124,82
4,81−0,04−0,83 %4,854,894,59
4,82−0,06−1,24 %4,884,934,74
4,850,122,47 %4,734,944,69
4,700,142,98 %4,564,774,51
4,60−0,04−0,87 %4,644,674,36
4,630,194,1 %4,444,684,42
4,53−0,32−7,06 %4,854,854,43
4,510,153,33 %4,364,554,22
4,45−0,07−1,57 %4,524,664,41
4,410,010,23 %4,404,624,39
4,510,132,88 %4,384,614,36
4,290,173,96 %4,124,324,11
4,05−0,19−4,69 %4,244,334,02
4,25−0,19−4,47 %4,444,604,18
4,420,153,39 %4,274,494,23
4,38−0,06−1,37 %4,444,504,33
4,280,040,93 %4,244,384,19
4,35−0,08−1,84 %4,434,504,17
4,22−0,04−0,95 %4,264,394,12
4,260,102,35 %4,164,344,09
4,28−0,08−1,87 %4,364,394,22
4,40−0,14−3,18 %4,544,584,31
4,50−0,08−1,78 %4,584,654,41
4,44−0,01−0,23 %4,454,594,28
4,37−0,10−2,29 %4,474,474,28
4,59−0,04−0,87 %4,634,754,50
4,69−0,07−1,49 %4,764,844,63
4,730,265,5 %4,474,814,41
4,590,051,09 %4,544,754,40
4,57−0,05−1,09 %4,624,744,44
4,740,255,27 %4,494,814,23
4,36−0,37−8,49 %4,734,844,13
5,840,183,08 %5,665,895,50
5,910,264,4 %5,655,955,61
5,800,223,79 %5,585,845,46
5,56−0,17−3,06 %5,735,825,49
5,640,061,06 %5,585,785,33
5,460,071,28 %5,395,645,29
5,440,020,37 %5,425,615,32
5,48−0,30−5,47 %5,785,795,39
5,77−0,02−0,35 %5,796,025,67
5,880,244,08 %5,645,975,64
5,77−0,10−1,73 %5,876,075,68
5,79−0,01−0,17 %5,805,915,48
5,720,172,97 %5,555,775,46
5,71−0,01−0,18 %5,725,895,59
5,64−0,20−3,55 %5,845,945,28
5,70−0,19−3,33 %5,896,155,65
5,62−0,22−3,91 %5,846,165,57
5,860,030,51 %5,836,035,48
5,900,264,41 %5,645,965,53
5,630,417,28 %5,225,655,18
5,24−0,05−0,95 %5,295,405,09
5,340,000 %5,345,415,20
5,30−0,28−5,28 %5,585,665,24
5,610,050,89 %5,565,755,52
5,50−0,03−0,55 %5,535,625,42
5,59−0,37−6,62 %5,966,015,52
5,91−0,28−4,74 %6,196,275,83
6,150,050,81 %6,106,275,87
6,010,376,16 %5,646,115,58
5,85−0,33−5,64 %6,186,275,79
6,14−0,30−4,89 %6,446,496,03
6,31−0,28−4,44 %6,596,646,18
6,55−0,02−0,31 %6,576,596,04
6,46−1,19−18,42 %7,657,676,29
8,04−0,38−4,73 %8,428,557,99
8,45−0,25−2,96 %8,708,878,33
8,840,333,73 %8,519,118,51
8,49−0,16−1,88 %8,658,718,37
8,590,080,93 %8,518,648,01
8,58−0,39−4,55 %8,979,068,26
8,960,091 %8,879,158,86
8,94−0,13−1,45 %9,079,088,82
9,06−0,21−2,32 %9,279,458,85
9,40−0,12−1,28 %9,529,579,23
9,520,060,63 %9,469,589,18
9,340,000 %9,349,549,05
9,54−0,01−0,1 %9,559,789,38
9,440,454,77 %8,999,548,98
8,990,343,78 %8,659,098,55
8,52−0,09−1,06 %8,618,888,38
8,660,222,54 %8,448,838,11
8,510,141,65 %8,378,578,22
8,430,293,44 %8,148,577,98
8,270,212,54 %8,068,537,95
7,84−0,02−0,26 %7,868,077,78
8,00−0,48−6 %8,488,837,97
8,58−0,16−1,86 %8,748,988,41
8,550,202,34 %8,358,728,12
8,310,060,72 %8,258,598,08
8,370,657,77 %7,728,407,53
7,47−0,44−5,89 %7,917,957,42
7,88−0,01−0,13 %7,898,057,73
8,03−0,05−0,62 %8,088,167,89
8,010,182,25 %7,838,267,79
7,880,455,71 %7,437,957,31
7,410,334,45 %7,087,516,98
6,990,030,43 %6,967,176,50
7,01−0,17−2,43 %7,187,526,82
7,152,1730,35 %4,987,374,94
4,800,153,12 %4,654,974,56
4,67−0,16−3,43 %4,834,944,59
4,860,306,17 %4,565,364,53
4,69−0,20−4,26 %4,894,974,63
4,93−0,07−1,42 %5,005,184,80
4,980,418,23 %4,575,044,50
4,64−0,22−4,74 %4,864,894,53
4,73−0,11−2,33 %4,845,034,44
5,020,122,39 %4,905,204,77
4,920,265,28 %4,665,024,49
4,83−0,32−6,63 %5,155,153,89
5,17−0,22−4,26 %5,395,395,08
5,220,132,49 %5,095,355,04
5,150,020,39 %5,135,425,08
5,26−0,14−2,66 %5,405,565,08
5,370,305,59 %5,075,475,00
5,040,112,18 %4,935,144,79
4,850,438,87 %4,424,894,40
4,390,081,82 %4,314,424,06
4,15−0,02−0,48 %4,174,343,89
4,210,5312,59 %3,684,243,64
3,700,246,49 %3,463,733,43
3,41−0,09−2,64 %3,503,643,33
3,63−0,19−5,23 %3,823,863,56
3,770,184,77 %3,593,823,49
3,55−0,12−3,38 %3,673,673,48
3,68−0,12−3,26 %3,803,803,57
3,74−0,02−0,53 %3,763,823,52
3,750,020,53 %3,733,833,62
3,720,102,69 %3,623,823,59
3,66−0,11−3,01 %3,773,793,49
3,770,030,8 %3,743,903,62
3,71−0,04−1,08 %3,753,853,64
3,71−0,01−0,27 %3,723,773,57
3,70−0,01−0,27 %3,713,853,50
3,700,3710 %3,333,973,28
3,220,020,62 %3,203,333,12
3,200,195,94 %3,013,282,97
3,01−0,15−4,98 %3,163,232,97
3,240,020,62 %3,223,423,15
3,22−0,01−0,31 %3,233,323,14
3,270,030,92 %3,243,323,12
3,220,000 %3,223,323,12
3,17−0,17−5,36 %3,343,483,12
3,260,010,31 %3,253,423,19
3,270,144,28 %3,133,433,06
3,15−0,05−1,59 %3,203,233,05
3,14−0,19−6,05 %3,333,373,06
3,350,092,69 %3,263,473,21
3,32−0,02−0,6 %3,343,433,24
3,35−0,19−5,67 %3,543,543,23
3,49−0,31−8,88 %3,803,853,17
3,900,4210,77 %3,484,103,46
3,420,236,73 %3,193,513,12
3,150,165,08 %2,993,212,97
2,95−0,01−0,34 %2,963,052,89
2,970,041,35 %2,933,012,85
2,92−0,04−1,37 %2,963,102,87
2,95−0,06−2,03 %3,013,072,87
2,980,113,69 %2,873,052,84
2,88−0,01−0,35 %2,893,012,80
2,900,155,17 %2,753,012,73
2,740,020,73 %2,722,872,66
2,710,082,95 %2,632,752,54
2,69−0,24−8,92 %2,932,952,64
2,900,113,79 %2,792,942,69
2,750,000 %2,752,872,69
2,760,134,71 %2,632,792,56
2,610,2810,73 %2,332,732,31
2,320,062,59 %2,262,352,18
2,24−0,09−4,02 %2,332,352,15
2,30−0,11−4,78 %2,412,562,26
2,340,010,43 %2,332,522,18
2,350,020,85 %2,332,392,22
2,370,083,38 %2,292,422,24
2,310,062,6 %2,252,342,19
2,23−0,04−1,79 %2,272,352,19
2,360,041,69 %2,322,482,31
2,41−0,09−3,73 %2,502,582,32
2,46−0,05−2,03 %2,512,602,39
2,550,031,18 %2,522,782,49
2,500,000 %2,502,602,43
2,510,000 %2,512,632,44
2,560,166,25 %2,402,602,33
2,350,010,43 %2,342,432,29
2,35−0,06−2,55 %2,412,512,29
2,300,031,3 %2,272,422,21
2,240,020,89 %2,222,352,17
2,230,062,69 %2,172,322,12
2,13−0,03−1,41 %2,162,252,05
2,14−0,10−4,67 %2,242,262,03
2,20−0,10−4,55 %2,302,312,14
2,31−0,05−2,16 %2,362,422,22
2,370,208,44 %2,172,452,12
2,05−0,06−2,93 %2,112,172,00
2,080,031,44 %2,052,182,00
2,090,062,87 %2,032,141,98
2,050,094,39 %1,962,091,87
1,94−0,02−1,03 %1,962,001,84
1,95−0,06−3,08 %2,012,121,92
1,93−0,05−2,59 %1,982,051,90
1,970,126,09 %1,852,001,78
1,88−0,14−7,45 %2,022,051,83
2,05−0,02−0,98 %2,072,162,00
2,030,062,96 %1,972,051,89
1,970,031,52 %1,942,031,81
1,790,126,7 %1,671,841,55
1,71−0,15−8,77 %1,861,871,68
1,860,158,06 %1,711,911,55
1,73−0,06−3,47 %1,791,831,66
1,81−0,37−20,44 %2,182,251,77
2,20−0,34−15,45 %2,542,741,95
2,530,000 %2,532,672,45
2,51−0,03−1,2 %2,542,552,40
2,48−0,08−3,23 %2,562,632,43
2,48−0,01−0,4 %2,492,562,36
2,45−0,02−0,82 %2,472,552,40
2,450,093,67 %2,362,482,25
2,340,166,84 %2,182,402,13
2,12−0,12−5,66 %2,242,282,08
2,26−0,01−0,44 %2,272,302,15
2,20−0,02−0,91 %2,222,372,10
2,24−0,14−6,25 %2,382,442,20
2,300,093,91 %2,212,362,14
2,250,198,44 %2,062,291,97
2,03−0,16−7,88 %2,192,231,98
2,17−0,12−5,53 %2,292,332,07
2,300,083,48 %2,222,412,19
2,260,041,77 %2,222,312,17
2,240,073,13 %2,172,282,09
2,17−0,04−1,84 %2,212,252,07
2,19−0,01−0,46 %2,202,252,08
2,15−0,10−4,65 %2,252,272,07
2,09−0,02−0,96 %2,112,172,00
2,10−0,12−5,71 %2,222,321,95
2,04−0,07−3,43 %2,112,161,97
2,09−0,35−16,75 %2,442,442,05
2,38−0,09−3,78 %2,472,542,35
2,460,124,88 %2,342,562,29
2,270,031,32 %2,242,322,17
2,250,156,67 %2,102,302,10
2,180,020,92 %2,162,222,07
2,160,041,85 %2,122,232,10
2,130,041,88 %2,092,162,05
2,130,062,82 %2,072,172,03
2,08−0,08−3,85 %2,162,252,02
2,060,073,4 %1,992,131,95
1,980,052,53 %1,932,071,87
1,970,042,03 %1,932,021,86
1,88−0,19−10,11 %2,072,081,79
2,020,031,49 %1,992,071,92
2,020,020,99 %2,002,101,89
1,990,199,55 %1,802,061,70
1,750,000 %1,751,801,60
1,790,137,26 %1,661,861,58
1,66−0,25−15,06 %1,911,921,60
1,800,2413,33 %1,561,851,51
1,66−0,01−0,6 %1,671,711,54
1,66−0,03−1,81 %1,691,771,61
1,790,042,23 %1,751,881,69
1,75−0,02−1,14 %1,771,811,64
1,76−0,01−0,57 %1,771,801,66
1,82−0,05−2,75 %1,871,901,77
1,870,010,53 %1,861,931,82
1,88−0,06−3,19 %1,941,991,82
1,94−0,04−2,06 %1,982,071,88
1,960,000 %1,962,001,82
1,89−0,05−2,65 %1,941,961,83
1,96−0,01−0,51 %1,972,011,87
1,98−0,03−1,52 %2,012,011,87
1,96−0,13−6,63 %2,092,091,90
2,09−0,10−4,78 %2,192,192,01
2,14−0,12−5,61 %2,262,332,09
2,21−0,02−0,9 %2,232,322,06
2,24−0,10−4,46 %2,342,442,16
2,290,4318,78 %1,862,371,79
1,880,031,6 %1,851,951,76
2,020,115,45 %1,912,091,77
1,890,010,53 %1,881,921,77
1,870,158,02 %1,721,921,68
1,820,021,1 %1,801,861,67
1,82−0,27−14,84 %2,092,221,77
1,970,010,51 %1,962,041,86
1,97−0,02−1,02 %1,992,091,93
1,98−0,09−4,55 %2,072,131,94
2,05−0,03−1,46 %2,082,111,95
2,08−0,14−6,73 %2,222,242,05
2,21−0,09−4,07 %2,302,352,17
2,27−0,05−2,2 %2,322,332,22
2,300,010,43 %2,292,372,26
2,32−0,01−0,43 %2,332,392,23
2,27−0,07−3,08 %2,342,382,23
2,290,041,75 %2,252,352,22
2,280,114,82 %2,172,342,14
2,23−0,01−0,45 %2,242,342,19
2,28−0,12−5,26 %2,402,432,24
2,38−0,05−2,1 %2,432,442,26
2,410,000 %2,412,472,35
2,45−0,02−0,82 %2,472,502,32
2,410,062,49 %2,352,452,22
2,270,020,88 %2,252,382,20
2,31−0,07−3,03 %2,382,512,26
2,40−0,04−1,67 %2,442,562,35
2,420,000 %2,422,532,38
2,45−0,04−1,63 %2,492,512,36
2,50−0,06−2,4 %2,562,602,38
2,52−0,27−10,71 %2,792,842,47
2,770,051,81 %2,722,842,59
2,650,114,15 %2,542,742,53
2,580,041,55 %2,542,692,48
2,51−0,09−3,59 %2,602,632,44
2,54−0,03−1,18 %2,572,632,45
2,60−0,06−2,31 %2,662,782,47
2,59−0,01−0,39 %2,602,642,47
2,67−0,01−0,37 %2,682,732,43
2,78−0,12−4,32 %2,903,012,70
3,01−0,28−9,3 %3,293,292,89
3,250,319,54 %2,943,472,94
Peržiūrėti daugiau

Pateikiami 2025-01-07–2026-06-23 laikotarpio duomenys.
Reikšmės „pokytis“, „atvira“, „uždara“, „didelė“ ir „maža“ pagrįstos NUVB dienos pirkimo kainos kursu.

Susijusios diskusijos

MikePetrov

prieš 4 dienas

Two Months In: Strong Growth From Nuvation Bio and Caris Life Sciences

For the past two months, I've been invested in Nuvation Bio and Caris Life Sciences. Their stock prices have performed very well.

Moc

prieš 5 mėnesius

NUVB reported preliminary net product revenue of $24.7 million for IBTROZI since launch

Nuvation Bio Inc. (NUVB) reported preliminary net product revenue of $24.7 million for IBTROZI since its launch in June 2025, with fourth quarter revenue reaching $15.7 million. The company said 432 patients started treatment on IBTROZI for advanced ROS1-positive non-small cell lung cancer since the drug’s launch, with 216 new patients beginning treatment in the fourth quarter. The treatment adoption rate is approximately six times greater than prior ROS1 tyrosine kinase inhibitor launches based on IQVIA data, according to the company. Nuvation Bio received a $25 million milestone payment from Nippon Kayaku in the fourth quarter following establishment of a reimbursement price in Japan. The company reported preliminary cash, cash equivalents and marketable securities of approximately $529.2 million as of December 31, 2025. On January 11, 2026, the company entered an exclusive license and collaboration agreement with Eisai Co., Ltd. to develop, register and commercialize taletrectinib for ROS1-positive non-small cell lung cancer in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India. IBTROZI received FDA approval on June 11, 2025, for treating adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer following Priority Review and Breakthrough Therapy designations. The company plans to continue enrollment of its phase 3 study evaluating safusidenib in high-grade and high-risk IDH1-mutant gliomas and pursue business development opportunities to expand its pipeline. The preliminary financial results are subject to adjustment pending completion of the company’s financial closing procedures. Nuvation Bio expects to issue full financial results for the fourth quarter and full year 2025 in March 2026.

Moc

prieš 7 mėnesius

Good news

$NUVB announced the publication of positive Phase 2 study results for safusidenib in treating grade 2 IDH1-mutant glioma patients. The findings were published in the journal Neuro-Oncology on November 8. The study evaluated 27 patients with IDH1-mutant grade 2 gliomas who had received no prior anticancer therapy except for resection or biopsy. The trial met its primary endpoint with an objective response rate of 44.4%. At 24 months, 87.9% of patients remained progression-free. Median progression-free survival had not been reached as of the March 10, 2023 data cutoff, with a median follow-up time of 28 months. The median duration of response could not be estimated because no progression events had occurred. Adverse events were described as mostly mild to moderate. Grade 3 or greater treatment-related adverse events occurred in five patients (18.5%). Three patients discontinued treatment due to adverse events, two of which investigators considered related to safusidenib. The company noted that a Good Clinical Practice noncompliance issue regarding adverse event collection was identified during the study. Safety data was subsequently re-investigated and re-collected according to study protocol. Safusidenib is an oral, brain-penetrant inhibitor of mutant IDH1. Nuvation Bio is progressing the ongoing G203 study in high-grade IDH1-mutant gliomas, with a protocol amendment planned to finalize the study as a global Phase 3 trial to support potential regulatory approvals. The company stated that as of September 15, 2025, 12 patients remained on treatment with safusidenib. Gliomas are the most common type of brain cancer in adults, with nearly 2,400 people diagnosed with IDH1-mutant gliomas annually in the United States.

BailyW

prieš 7 mėnesius

Up?

Has this got anymore juice? Holding nicely. What do people think?

Šiame puslapyje gali būti bendruomenės sukurto turinio, už kurį „Trading 212“ neatsako. Visada atlik savo tyrimą. „Trading 212“ teikia tik vykdymo paslaugą, bet neteikia investavimo konsultacijų ar portfelio valdymo paslaugų.

Susijusios finansinės priemonės

Bank of New York Mellon

+29,06 (+24,50 %)

First Western Financial

+6,12 (+24,90 %)

Grab

−0,24 (−6,56 %)

Hercules Capital

+0,53 (+3,59 %)

Burford Capital

−0,26 (−5,75 %)

Credit Acceptance

+170,29 (+40,21 %)

Jasper Therapeutics

−0,4021 (−45,89 %)

NewtekOne

+2,91 (+26,58 %)

Better Home & Finance Holding

−8,97 (−25,18 %)

Coincheck Group

+0,55 (+37,16 %)

Invesco Mortgage Capital

−0,28 (−3,47 %)

GCM Grosvenor

+2,29 (+23,37 %)

Investavimas be komisinių visiems

Pirk ir parduok Nuvation Bio Inc +0,24 $ (4,17 %) ir daugiau nei 13 000 pasaulinių vertybinių popierių ir ETF

Gali būti taikomi kiti mokesčiai. Žr. mūsų sąlygas ir mokesčius.

Peržiūrėk mūsų sąlygas ir mokesčius čia

phone

Įsigyk vertybinių popierių iškart

Pasirink mėgstamiausią įmonę

Pasirink, kiek investuoti

Gauk akcijų per kelias sekundes

Turto kaupimas – įprotis.
Automatizuokite jį naudodami Pies.

Investuok į paruoštus arba susikurk savo investicijų rinkinius, pasirinkdamas iš daugybės vertybinių popierių ir ETF

Sužinok daugiau

Sužinok daugiau

Žiūrėti vaizdo įrašą

Turėk net brangiausių akcijų, tokių kaip „Google“, „Amazon“ ir „Apple“

Žiūrėti vaizdo įrašą

Flag fr

„Euronext“
Paryžius

Flag us

NYSE,
NASDAQ

Flag de

Xetra,
Gettex

Flag nl

Euronext Amsterdam

Flag es

Bolsa
de Madrid

Flag at

Wiener
Börse

Flag uk

Londono vertybinių popierių birža

Flag pt

„Euronext Lisbon“

Flag fr

„Euronext“
Paryžius

Flag us

NYSE,
NASDAQ

Flag de

Xetra,
Gettex

Flag nl

Euronext Amsterdam

Flag es

Bolsa
de Madrid

Flag at

Wiener
Börse

Flag uk

Londono vertybinių popierių birža

Flag pt

„Euronext Lisbon“

Peržiūrėk visas prekybos priemones

Pagalba visą parą

29 sekundžių vidutinis atsako laikas

Pradėk kaupti turtą jau dabar

Prisijunk prie daugiau nei 5 mln. naudotojų

Atsisiųsti programėlę

Atidaryti sąskaitą

Atsisiųsk mobiliąją programėlę

qr-code

Visi pateikti statistiniai duomenys yra globalūs. Klientų skaičius atspindi finansuotas sąskaitas.

Puiku

Įvertinta 4,6/5, remiantis 95 591 atsiliepimais apie

Trustpilot

Įvertinta 4,6/5, remiantis 95 591 atsiliepimais apie

Trustpilot

Pakviestas

Love the Trading 212 App it’s great fun…

Love the Trading 212 App it’s great fun to use and it’s really intuitive in helping you to monitor your investments as they grow!

Richard Knights

prieš 4 d.

Pakviestas

Safe,simple and easy

Great website, easy to use. Regular updates. Sit back and do nothing. Couldn’t be simpler. Very happy.

Nigel

prieš 4 d.

Pakviestas

Great app and easy to use

The Trading 212 app is easy to use and I like the fact you can see your investment grow on a daily basis.

Hazel

prieš 4 d.

Pakviestas

Very easy account making/saving…

It’s been so easy to create accounts and start investing/saving would recommend to anyone

BLaw

prieš 4 d.

Pakviestas

Best app

This investment app is very easy to use and has a user-friendly interface. I feel confident knowing my money is secure, and the investment process is simple and straightforward. The customer support is also responsive and helpful whenever needed. Highly recommended for anyone looking for a reliable investment platform!

Teesside Customer

prieš 4 d.

Pakviestas

Easy and stress free

Investing is made very easy with Trading 212.

HMN

prieš 4 d.

Pakviestas

Easy to use

Easy to set up easy to use deposit and take out

Mr S Axford

prieš 4 d.

Pakviestas

The best trading app out there

The best trading app out there. No question

Paul

prieš 4 d.

Pakviestas

Easy to use

Easy to use. I love it

Mark White

prieš 4 d.

Pakviestas

Low fees ETFs + on of the best interest…

Low fees ETFs + on of the best interest rate on cash attached

Pavel Voronkin

prieš 4 d.

Pakviestas

Easy to use

Easy to use, recommend if you’re interested in investing

Ben

prieš 4 d.

Pakviestas

Very helpful and professional and my…

Very helpful and professional and my query was dealt with quickly and efficiently.

Mrs Mazzotta

prieš 4 d.

Pakviestas

All good!

Till now, almost a year after start using it, the experience has been going very well. No issues with any of the activities I needed to perform, friendly user interface and enough tools. I'm also glad that looks like the team ears the community. Keep up the good work.

Hugo Valadas

prieš 4 d.

Pakviestas

A great platform to invest

A great platform to invest. The app is easy to navigate. Easy to transfer money.

Simon C

prieš 4 d.

Used stocks and shares ISA as well as…

Used stocks and shares ISA as well as Cash ISA. Like the stocks interface, info about financials of the companies. It does not work very reliably on niche stocks or ETFs, but I would be surprised if it did. Also it tracks the ISA limits, ISAs are flexible. So can take money in and out all the time. Withdrawals are very quick. They tell it may take few businesses days, but usually goes through in a few minutes (if not seconds). Cash ISA interest was high, not it is not really, but I suppose it is a price for ability to withdraw anytime. It would be nice if I could buy government bonds there as stocks and shares ISA product.

Ruslan Lytvynov

prieš 5 d.

Pakviestas

Great experience.

Orders execution is really smooth, level of transparency is amazing when it comes to clear track of transactions and pies is very helpful. If they just can enable higher freedom when it comes to communication between members in one community/pie, it will be amazing.

ahmed elsayes

prieš 5 d.

Pakviestas

Great app

Great app. Very easy to use. No complications atall

customer

prieš 5 d.

Pakviestas

Great even for beginners

Really easy to use and track investments. Fees are clear and fair. The ability to communicate with other investors for support is a good feature, especially for beginners. I'm a newbie to stocks and shares, this app has been perfect to learn with as well as actual investments.

Paul Carr

prieš 5 d.

Pakviestas

T212 - The SIPP’er heros.

The Trading 212 team pretty much does all the heavy lifting when setting up a SIPP, you do need to supply the obvious details, and will most likely need to respond to your previous pension provider to confirm your sure with the transfer. But as far as pension pot transfers go, T212 is fantastic! They looked into potential loss of protected terms and brought this up quickly for me to make a decision. The response time from the team is really quick and professional- I cant recommend them enough. I also really like the SIPP interface on the app, its really easy to understand and is seamless with your other investment accounts. 10/10.

Thomas Warren

prieš 5 d.

Pakviestas

Great site makes investing very easy…

Great site makes investing very easy and exciting, still a little confused on some things but getting there, thanks

Mr Cursons

prieš 5 d.

Pateikiami keli teigiami mūsų klientų atsiliepimai

Mūsų apdovanojimai

Dažniausiai užduodami klausimai

Kokia yra Nuvation Bio (NUVB) akcijos kaina?

Dabartinė Nuvation Bio (NUVB) kaina yra 6 $.

Koks yra NUVB52 savaičių maksimumas?

52 savaičių maksimumas NUVB yra 9,78 $.

Koks yra NUVB 52 savaičių žemiausias lygis?

52 savaičių žemiausias NUVB kursas yra 1,78 $.

Koks yra NUVB savaitės rezultatas?

Per pastarąją savaitę NUVB kaina pasikeitė 17,19 %.

Koks yra NUVB mėnesio našumas?

Per pastarąjį mėnesį NUVB kaina pasikeitė 27,12 %.

Koks yra NUVB 3 mėnesių rezultatas?

Per pastaruosius tris mėnesius NUVB kaina pasikeitė 42,18 %.

Koks yra NUVB 6 mėnesių rezultatas?

Per pastaruosius šešis mėnesius NUVB kaina pasikeitė −37,11 %.

Koks yra NUVBmetinis našumas?

Per pastaruosius metus NUVB kaina pasikeitė 204,57 %.